Wirkstoffe & Arzneimittelsicherheit

Wechselwirkungen · Tivicay

Tivicay 10 mg film-coated tablets Tivicay 25 mg film-coated tablets Tivicay 50 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 7–8

HOS-129161 · Präparat HOS-096689

7  Efavirenz  (historical In the presence of integrase class resistance controls) alternative combinations that do not include (induction of UGT1A1 and efavirenz should be considered (see section 4.4). CYP3A enzymes) Nevirapine Dolutegravir  The recommended adult dose of dolutegravir is (Not studied, a similar 50 mg twice daily when co-administered with reduction in exposure as nevirapine. In paediatric patients the weight-based observed with efavirenz is once daily dose should be administered twice expected, due to induction) daily. In the presence of integrase class resistance alternative combinations that do not include nevirapine should be considered (see section 4.4). Rilpivirine Dolutegravir  No dose adjustment is necessary. AUC  12% Cmax  13% Cτ  22% Rilpivirine  Nucleoside Reverse Transcriptase Inhibitors Tenofovir Dolutegravir  No dose adjustment is necessary. AUC  1% Cmax  3% Cτ  8% Tenofovir  Protease Inhibitors Atazanavir Dolutegravir  No dose adjustment is necessary. AUC  91% Cmax  50% Tivicay should not be dosed higher than 50 mg Cτ  180% twice daily in combination with atazanavir (see section 5.2) due to lack of data. Atazanavir  (historical controls) (inhibition of UGT1A1 and CYP3A enzymes) Atazanavir/ritonavir Dolutegravir  No dose adjustment is necessary. AUC  62% Cmax  34% Tivicay should not be dosed higher than 50 mg Cτ  121% twice daily in combination with atazanavir (see section 5.2) due to lack of data. Atazanavir  Ritonavir  (inhibition of UGT1A1 and CYP3A enzymes) Tipranavir/ritonavir Dolutegravir  The recommended adult dose of dolutegravir is (TPV+RTV) AUC  59% 50 mg twice daily when co-administered with Cmax  47% tipranavir/ritonavir. In paediatric patients the Cτ  76% weight-based once daily dose should be (induction of UGT1A1 and administered twice daily. CYP3A enzymes) In the presence of integrase class resistance this combination should be avoided (see section 4.4). Fosamprenavir/ Dolutegravir  No dose adjustment is necessary in the absence of ritonavir (FPV+RTV) AUC  35% integrase class resistance. Cmax  24% In the presence of integrase class resistance Cτ  49% alternative combinations that do not include (induction of UGT1A1 and fosamprenavir/ritonavir should be considered. CYP3A enzymes)

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): tenofovir (HOS-088083) atazanavir (HOS-086180) protease (HOS-085623) rilpivirine (HOS-088090) efavirenz (HOS-087947) nevirapine (HOS-088064) fosamprenavir (HOS-086182) ritonavir (HOS-084521) tipranavir (HOS-086184)